Medicis Pharmaceutical Corp. (MRX) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $43.98 --0%
Financial Fact:
Net product revenues: 179.13M
Today's EPS Names:
MAXN, CSTR, ACU, More
Financial Fact:
Net product revenues: 179.13M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q3 EPS of $0.56, $0.05 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $187.06 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
